Navigation Links
Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
Date:5/6/2010

n cancer is one of the most common gynaecologic malignancies and the fifth most frequent cause of cancer death in women, with most of the cases occurring in women between 50 and 75 years of age. Overall, ovarian cancer accounts for 4% of all cancer diagnoses in women and 5% of all cancer deaths. Approximately 26,000 new cases and 17,000 deaths from this disease are estimated in the European community every year (Source: Gynaecologic Oncology 2004; 92:819-26). The National Cancer Institute estimates that in 2009, in the United States alone, there were 21,550 news cases of ovarian cancer and 14,600 related deaths.

About AEZS-108

AEZS-108 represents a new targeting concept in oncology using a cytotoxic peptide conjugate which is a hybrid molecule composed of a synthetic peptide carrier and a well-known cytotoxic agent, doxorubicin. The design of this product allows for the specific binding and selective uptake of the cytotoxic conjugate by LHRH-receptor-positive tumors. The binding of AEZS-108 to cancerous cells that express these receptors results in its accumulation and preferential uptake in the malignant tissue.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements invol
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... 02, 2015 Research and Markets ... of the "2015 Strategies in the ... to their offering. This new ... immunoprotein diagnostic market, including emerging tests, technologies, ... profiles of leading suppliers. During ...
(Date:6/3/2015)... Minn. , June 3, 2015 ... that supports the entire spectrum of clinical research, is ... iMedNet eClinical technology platform will ... by the end of this month.  iMedNet ... – built from the ground up by MedNet Solutions, ...
(Date:6/3/2015)... 2015 Typical racks for laboratory freezers ... and depths often taking up unnecessary room in already ... Low 5 Box Freezer Racks offer a customizable ... freezer storage boxes and freezers. , “These racks ... experiments or multiple people because users can configure freezer ...
(Date:6/3/2015)... 2015 Green Earth Energy has restructured ... support the RCBC Waste to Energy system. Paul ... the family business, http://www.greenearthwaste.com which has been ... added recycling to their waste collection services in 2012 ... the Fortune 500 companies with manufacturing plants in West ...
Breaking Biology Technology:United States Strategies in the Immunoprotein Diagnostic Testing Market Report 2015 2MedNet Announces "2015 Feature 1" Release Of iMedNet eClinical 2Freezer Space Can Now Be Configured Your Way with New Modular Freezer Racks 2
... BioNeutral Group, Inc. ("BioNeutral") (OTC Bulletin Board: BONU), ... that at ATS Labs, using a Quantitative Disk ... (C.diff) spores, BioNeutral,s Ygiene(TM) Hospital Grade antimicrobial delivered ... Clostridium Difficile, an extremely dangerous and difficult to ...
... Novavax, Inc. (Nasdaq: NVAX ) ... their joint venture in India under the agreement signed ... joint venture, called CPL Biologicals Pvt. Ltd., will develop ... using technology contributed from Novavax and Cadila Pharmaceuticals. ...
... safety of their drinking water for granted, that ordinary tap ... of Tel Aviv University,s School of Physics and Astronomy. ... natural disaster or sabotage, the physicist has developed a new ... water supply in real time. Modifying special fibers ...
Cached Biology Technology:BioNeutral's Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase 2BioNeutral's Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase 3Cadila Pharmaceuticals Launches Joint Venture With Novavax in India 2Cadila Pharmaceuticals Launches Joint Venture With Novavax in India 3Cadila Pharmaceuticals Launches Joint Venture With Novavax in India 4Monitoring water through a snake's eyes 2Monitoring water through a snake's eyes 3
(Date:5/29/2015)... May 28, 2015 Research and Markets ... the "Facial Recognition Market by Solution, by ... Forecast to 2020" report to their offering. ... facial recognition technology become more efficient and cost ... traction and investment from the commercial sector. The ...
(Date:5/27/2015)... , May 27, 2015   ... medication safety systems and image documentation solutions ... of comprehensive, technologically-advanced automation solutions, is pleased ... integration. The Codonics® Safe Label System® (SLS), ... in conjunction with the Omnicell Anesthesia Workstation, ...
(Date:5/25/2015)... -- Australia,s market for wearable technologies is considered to be ... of several trials and prototypes. The release of the ... ignite interest in wearables as well as accelerate sales ... This in turn will spur greater innovation from other ... vendors and distributors. Photo - ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4
... reserves such as gold, diamond and natural gas isn,t ... look. Now researchers at Tel Aviv University have modernized the ... signs of lucrative resources that could lurk beneath our feet. ... first time, Prof. Lev Eppelbaum of TAU,s Department of ...
... Bethesda, MDA new research report published in The ... and scientists better understand a rare genetic disease that ... decreased vision called Enhanced S-Cone Syndrome or Goldman-Favre Syndrome. ... genes responsible for the healthy renewal of rods and ...
... had officials along the East Coast preparing for mass ... the University of Delaware were grabbing their best data ... It was a rare opportunity for the scientists ... as Irene threatened to be the biggest hurricane to ...
Cached Biology News:The geophysicist's guide to striking it rich 2Scientists unravel the cause of rare genetic disease: Goldman-Favre Syndrome explained 2Hurricane Irene: Scientists collect water quality and climate change data from huge storm 2
... syringe pump series combines Harvard Apparatuss best pump ... a wide range of configuration options. A lookup ... of syringes from all the major manufacturers. A ... the pertinent information from across the lab. All ...
ACS Reagent Grade C 19 H 14 O 5 S Formula Weight: 354.38 PRODUCT SPECIFICATIONS Form: Rust/red crystalline powder Clarity of Solution: Passes test Visual Transition Interval: pH 6.8 - Yellow pH 8.2...
... Vector NTI allows you to store and ... data in a secure central relational database. ... creates an invaluable resource for clone tracking ... easily for immediate analysis. LabShare software integrates ...
... Protein A and Protein G bind ... immunoglobulins. Protein A and Protein G conjugates ... purify immunoglobulins (antibodies) and immunoglobulin subtypes from ... and other biological fluids. These reagents are ...
Biology Products: